- Temsirolimus2008 | Third Faculty of Medicine
- Nontuberculous mycobacterial infection after therapy with temsirolimus for metastatic renal cell carcinoma2013 | First Faculty of Medicine
- Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma2018 | Third Faculty of Medicine
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study2016 | First Faculty of Medicine
- Biological treatment of renal cell cancer2012 | First Faculty of Medicine
- Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma2023 | First Faculty of Medicine
- Prognostic and predictive factors in metastatic renal cell cancer treated with targeted therapies2011 | First Faculty of Medicine
- Kidney cancer. What is the next step after failure of treatment with angiogenesis inhibitors?2010 | Second Faculty of Medicine
- Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region2012 | First Faculty of Medicine
- Targeted therapy of metastatic renal cell carcinoma and treatment sequences: a current view +12014 | First Faculty of Medicine
- Renal cell carcinoma 20152015 | First Faculty of Medicine
- Therapy possibilities for elderly patients with metastatic renal cell carcinoma2016 | First Faculty of Medicine
- Integration of surgery and molecular targeted therapy in advanced renal cell carcinoma2011 | Second Faculty of Medicine
- Ibrutinib jako přemostění k alogenní transplantaci kostní dřeně2017 | Publication without faculty affiliation
- Molecular Targets for Cancer Therapy in the PI3K/AKT/mTOR Pathway2014 | Faculty of Medicine in Pilsen
- Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database2012 | First Faculty of Medicine
- Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents2014 | First Faculty of Medicine